Skip to main content
. Author manuscript; available in PMC: 2015 Jun 15.
Published in final edited form as: Clin Cancer Res. 2014 Apr 11;20(12):3289–3298. doi: 10.1158/1078-0432.CCR-13-3360

Table 1. Subject Characteristics by Treatment Group.

Placebo
(N = 12)		 Erlotinib
(N = 18)		 Erlotinib + Sulindac
(N = 16)		 Test of Equality1
Age
 Median 59 64 49 .8976
 range 33 - 86 44 -73 49 - 68
N % N % N %
Gender
 Female 3 25 4 22 3 19 .9924
 Male 9 75 14 78 13 81
Tumor Site
 Oral Cavity 8 67 9 50 9 56 .6606
 Oropharynx 3 35 5 28 6 38
 Hypopharynx 0 0 2 11 0 0
 Larynx 1 8 2 11 1 6
Tumor (T) Stage2
 1 1 9 0 0 0 0 .2371
 2 5 45 3 18 3 20
 3 3 28 4 24 5 33
 4 2 18 10 59 7 47
Nodal (N) Stage3
 0 7 70 8 44 6 40 .3389
 1 1 10 4 22 6 40
 2 2 20 6 33 2 13
 3 0 0 0 0 1 7
p16 Status4
 Positive 1 11 3 20 0 0 .3579
 Negative 10 89 12 80 11 100
1

Wilcoxon Test for age, Fisher's exact two-tailed test for others

2

T classification was not available for 3 subjects.

3

N classification was not available for 3 subjects.

4

p16 status was not available for 9 patients. Among 14 oropharynx cases, 11 were p16(-), 2 were p16(+), and 1 was unknown.